UBS will raise PT from $315 to $326 with Amgen Inc. (AMGN) to maintain a neutral rating
Amgen Inc. (NASDAQ:amgn) is one of Most underrated blue chip stock to buy according to hedge funds. On July 21st, UBS analyst Trung Huynh raised the Amgen Inc. (NASDAQ: AMGN) company’s price target from $315 to $326.
A pharmacist who fills up the prescriptions for complex drugs developed by the company.
The company told investors in the research notes it expects Amgen Inc. (NASDAQ: AMGN) to offer small beats in its second quarter results after two consecutive quarter beats. But it also continues to believe that rare disease products can be bumpy.
Amgen Inc. (NASDAQ: AMGN) is a biotechnology company that discovers, develops, manufactures and sells human treatments. We offer new treatments to patients with complex cancer, especially in areas with unfulfilled needs.
Although we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater promotion potential and pose a risk of decline. If you’re looking for a highly undervalued AI stock that can make a significant profit from the tariff and supervision trends of the Trump era, check out our free report. Best Short-Term AI Stocks.
Read next: 30 stocks that double in three years and 11 Hidden AI Strains Buy Now.
Disclosure: None. This article was originally published Insider Monkey.